EUVIMEDEUVIMED entdecken
Vergleichsstudie

Association of Race and Ethnicity With High-Potency P2Y12 Inhibitors Prescription Among Patients With Acute MI Undergoing PCI: An Analysis From the CathPCI Registry

Hend Mansoor iD, Rebecca Young iD, Lisa A Kaltenbach, Daniel M Wojdyla, Binita Shah iD, Ian C Gilchrist iD, Jennifer A Rymer iD, Islam Y Elgendy iD

Circulation: Cardiovascular Interventions · 2026

DOI: 10.1161/circinterventions.125.015600 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Circulation: Cardiovascular Interventions, 2026. Verfasst von Hend Mansoor und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Science (H.M.), University of Kentucky, Lexington. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Purinergic P2Y Receptor Antagonists, Healthcare Disparities, Practice Patterns, Physicians'. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Racial and ethnic disparities exist in postacute myocardial infarction (AMI) care. High-potency P2Y12 inhibitors use among patients with AMI who undergo percutaneous coronary intervention (PCI) carries a class I indication in the guidelines. This study aims to examine racial and ethnic differences in high-potency P2Y12 inhibitor prescription on discharge among patients with AMI undergoing PCI. METHODS: Using data from the NCDR Cath PCI registry, we identified consecutive patients with AMI who underwent PCI from April 2018 to June 2023. Likelihood of high-potency P2Y12 inhibitor prescription on discharge was assessed using logistic regression models adjusted for social deprivation index and other patient- and procedure-related variables. RESULTS: Among 1 662 387 patients hospitalized with AMI and who underwent PCI, 165 579 (9.9%) were Black, 58 595 (3.5%) were Asian, and 1 302 576 (78.3%) were of White race, while 135 637 (8.1%) were of Hispanic ethnicity. At discharge 876 078 (52.7%) were prescribed a high-potency P2Y12 inhibitor. Compared with White patients, Black patients were less likely (adjusted odds ratio, 0.93 [95% CI, 0.92–0.94]), while Asians were more likely (adjusted odds ratio, 1.08 [1.07–1.10]) to have a high-potency P2Y12 inhibitor discharge prescription. Compared with non-Hispanics, Hispanic patients were less likely to have a high-potency P2Y12 inhibitor discharge prescription (adjusted odds ratio, 0.95 [95% CI, 0.93–0.96). CONCLUSIONS: In a contemporary national registry of hospitalized patients with AMI who underwent PCI, Black and Hispanic patients were less likely to be discharged on a high-potency P2Y12 inhibitor irrespective of socioeconomic status. These findings highlight an opportunity to achieve equity in guideline-directed AMI pharmacotherapies to improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionPurinergic P2Y Receptor AntagonistsHealthcare DisparitiesPractice Patterns, Physicians'Myocardial InfarctionPlatelet Aggregation InhibitorsHumansMaleFemaleRegistriesMiddle AgedAgedRace FactorsUnited StatesTreatment OutcomeRisk FactorsRisk AssessmentPatient DischargeWhite PeopleTime FactorsBlack or African AmericanHispanic or LatinoDrug PrescriptionsWhite

Stichwörter der Autor:innen

ethnicitymyocardial infarctionpercutaneous coronary intervention

Substanzen

Purinergic P2Y Receptor AntagonistsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy Practice and Science (H.M.), University of Kentucky, Lexington.
  • Division of Cardiology, Duke University, Durham, NC (R.Y., L.A.K., D.M.W., J.A.R.).
  • Duke Clinical Research Institute, Durham, NC (R.Y., L.A.K., D.M.W., J.A.R.).
  • Leon H Charney Division of Cardiology, NYU Grossman School of Medicine, New York, NY (B.S.).
  • Section of Cardiovascular Medicine, Heart and Vascular Center, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Hanover, NH (I.C.G.).
  • Division of Cardiovascular Medicine, Gill Heart and Vascular Institute (I.Y.E.), University of Kentucky, Lexington.

ORCID-Profile: Hend Mansoor, Rebecca Young, Binita Shah, Ian C Gilchrist, Jennifer A Rymer, Islam Y Elgendy

Zitieren

APA

Mansoor, H., Young, R., Kaltenbach, L. A., Wojdyla, D. M., Shah, B., Gilchrist, I. C., Rymer, J. A., & Elgendy, I. Y. (2026). Association of Race and Ethnicity With High-Potency P2Y12 Inhibitors Prescription Among Patients With Acute MI Undergoing PCI: An Analysis From the CathPCI Registry. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.125.015600

Vancouver

Mansoor H, Young R, Kaltenbach LA, Wojdyla DM, Shah B, Gilchrist IC, et al. Association of Race and Ethnicity With High-Potency P2Y12 Inhibitors Prescription Among Patients With Acute MI Undergoing PCI: An Analysis From the CathPCI Registry. Circulation: Cardiovascular Interventions. 2026. doi:10.1161/circinterventions.125.015600

BibTeX
@article{Mansoor2026,
  author = {Mansoor, Hend and Young, Rebecca and Kaltenbach, Lisa A and Wojdyla, Daniel M and Shah, Binita and Gilchrist, Ian C and Rymer, Jennifer A and Elgendy, Islam Y},
  title = {Association of Race and Ethnicity With High-Potency P2Y12 Inhibitors Prescription Among Patients With Acute MI Undergoing PCI: An Analysis From the CathPCI Registry},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2026},
  doi = {10.1161/circinterventions.125.015600}
}
Kostenlos starten →